Tumor Xenografts

Dear Colleague，

Mouse models are used in preclinical and translational research to investigate events that initiate and drive cancer progression, as well as to evaluate new therapies. There is a wide spectrum of mouse models to choose from, depending on the intended experimental purpose. However, there is a growing realization that the therapeutic results obtained using mouse models often do not predict efficacy in the clinic. One approach to improving the modeling of patient tumors and their therapeutic responses has been to develop cohorts of patient-derived xenograft tumors (PDX models). PDX models, engrafted into immunodeficient SCID mice, are thought to best represent the diversity and heterogeneity of the patient population. A major shortcoming of these models is the lack of adaptive immune responses in SCID mice, although this is being addressed by the use of so-called humanized SCID mice. The current status of PDX models is the focus of this Special Issue. We welcome articles that will review and present up-to-date information on the characterization and advantages of PDX models, especially as to how well they actually recapitulate the diversity of patient tumors, the evaluation of new therapeutics, biomarker discovery, use as avatars in personalized medicine approaches, and ideas as to how to improve these valuable models.

Dr. Bonnie Hylander
Prof. Dr. Elizabeth Repasky
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.